Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.030
-0.190 (-8.56%)
Nov 21, 2024, 12:34 PM EST - Market open
Fate Therapeutics Employees
Fate Therapeutics had 181 employees as of December 31, 2023. The number of employees decreased by 370 or -67.15% compared to the previous year.
Employees
181
Change (1Y)
-370
Growth (1Y)
-67.15%
Revenue / Employee
$74,293
Profits / Employee
-$984,702
Market Cap
231.44M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Zynex | 1,100 |
Anika Therapeutics | 357 |
Poseida Therapeutics | 330 |
NeuroPace | 171 |
Mersana Therapeutics | 123 |
Ocugen | 65 |
Artiva Biotherapeutics | 43 |
Eton Pharmaceuticals | 30 |
FATE News
- 20 hours ago - Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha
- 3 days ago - Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence - GlobeNewsWire
- 8 days ago - Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 11 days ago - Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - GlobeNewsWire
- 12 days ago - Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting - GlobeNewsWire
- 16 days ago - Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference - GlobeNewsWire